Page 1

QIAGEN QIAGEN exceeds outlook in first quarter 2021 results , reaffirms sales growth and profitability outlook for full - year 2021 • Q1 2021 net sales rise 52 % ( 48 % CER ) to $ 567.2 million , exceeds outlook for at least 45 % CER growth ; adj . EPS up 94 % to $ 0.66 ( $ 0.65 CER ) , exceeds outlook for ~ $ 0.60-0.62 CER • • 16 % CER growth to $ 364 million from non - COVID product groups , represent 64 % of total sales , while COVID - 19 product group sales rise 186 % CER to $ 203 million Q1 2021 operating cash flow rises over 700 % to $ 128.6 million , free cash flow of $ 82.3 million Reaffirming full - year 2021 outlook for ~ 18-20 % CER net sales growth and ~ $ 2.42-2.46 CER adjusted diluted EPS Venlo , the Netherlands , May 3 , 2021 - QIAGEN N.V. ( NYSE : QGEN ; Frankfurt Prime Standard : QIA ) announced strong results of operations for the first quarter of 2021 , exceeding the goals for net sales and adjusted earnings per share . Net sales in the first quarter of 2021 rose 52 % ( + 48 % at constant exchange rates , CER ) to $ 567.2 million from the first quarter of 2020 , and faster than the outlook of at least 45 % CER growth . Adjusted earnings per share ( EPS ) were $ 0.66 ( $ 0.65 CER ) against the outlook of about $ 0.60-0.62 CER , and rose 94 % from $ 0.34 in the first quarter of 2020 . " Our results for the first quarter of 2021 once again show QIAGEN continuing to execute and beat the outlook set for sales and earnings growth , " said Thierry Bernard , Chief Executive Officer of QIAGEN N.V. " This performance was particularly driven by 16 % CER growth in sales of non - COVID product groups that represented 64 % of our sales . We are pleased with trends showing that research laboratories around the world are increasingly returning to work and clinical labs are moving beyond COVID testing . This progress underlines the point that QIAGEN's business is COVID relevant , but not COVID dependent . " Our teams continue to show great dedication in meeting the ongoing demand for QIAGEN solutions to support the global response to the COVID - 19 pandemic . This includes launching new solutions for both COVID - 19 testing , and many of which have non - COVID applications . " We have made multiple product expansions to our non - COVID related portfolio , including the launch of a Lyme Disease test based on QuantiFERON technology with our partner DiaSorin , bringing the QIAcube Connect sample processing instrument to clinical customers and releasing the QIAsphere solution to offer cloud - based platform connectivity for QIAstat - Dx and QIAcube Connect as a start , and for use in the future on other instruments and automation systems in the future . As we look forward to delivering on our commitments for 2021 , we are well on track to positioning QIAGEN for sustainable growth and creating greater value beyond the pandemic . " 1